Dr. Katie Murray discusses the diagnosis and management of non–muscle invasive bladder cancer, emphasizing cystoscopy and initial TURBT as the standard for accurate diagnosis and pathology. She notes that low-grade bladder cancer has a high recurrence rate, often within the first year. Traditionally, recurrences required repeat surgery, but newer FDA-approved intravesical chemoablative therapies now offer an alternative. These options may help some patients avoid returning to the operating room while effectively treating recurrent disease.
Belzutifan Moves Earlier in Kidney Cancer Care
Dr. Laurence Albiges outlines how belzutifan is reshaping kidney cancer treatment across disease stages. In the adjuvant setting, adding belzutifan
